Idarucizumab (Drug Plan Submission)


( Last Updated : May 17, 2016)
Generic Name:
Idarucizumab (Drug Plan Submission)
Project Status:
Withdrawn
Therapeutic Area:
Reversal of dabigatran anticoagulant effects
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Call for patient/clinician input open:
Brand Name:
Praxbind
Project Line:
Reimbursement Review
Project Number:
SR0492-000
Call for patient/clinician input closed:

Details


Submission Type:
Initial
Indications:
Reversal of dabigatran anticoagulant effects